surmount 5 tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Tirzepatide's Surmount-4 Trial Reveals Groundbreaking

Exogenous GLP1 infusion decreased energy intake, decreased appetite, and decreased brain responses to food anticipation

Langmuir 19:55675569

15 Minutes including consultation No anaesthetic necessary Patients may experience slight discomfort during administration

Switching from one to the other is increasingly common

Evidence of an association between the Arg72 allele of the peptide YY and increased risk of type 2 diabetes

This treatment is suitable for adults who haven't seen significant results through diet and exercise and those with weight-related conditions like type 2 diabetes, high blood pressure, or cholesterol issues